Hodgkin lymphoma Medical Services in China

Hodgkin lymphoma (HL) is a distinct type of B-cell-derived hematologic malignancy characterized by the presence of diagnostic Reed-Sternberg cells within a reactive inflammatory microenvironment. Unlike non-Hodgkin lymphomas, HL exhibits highly stereotyped histopathology and predictable clinical behavior, typically presenting with painless, progressive lymphadenopathy—most commonly in cervical or supraclavicular regions. The disease is classified into two main subtypes: classical Hodgkin lymphoma (cHL), accounting for over 95% of cases, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rarer, indolent variant with different biology and management. Pathogenesis involves malignant transformation of germinal center or post-germinal center B lymphocytes, driven by genetic alterations (e.g., chromosome 9p24.1 amplification leading to PD-L1/PD-L2 overexpression), Epstein-Barr virus (EBV) infection in ~30–50% of cases (especially in endemic or immunocompromised populations), and dysregulated immune surveillance. Chronic inflammation, cytokine signaling (e.g., NF-κB, JAK/STAT), and tumor–microenvironment crosstalk further support survival and proliferation of Reed-Sternberg cells. Epidemiologically, HL displays a bimodal age distribution—peaking in young adults aged 20–34 years and again in individuals over 55—suggesting differing etiologic drivers across age groups. Globally, incidence ranges from 2–3 cases per 100,000 persons annually, with higher rates in high-income countries. In China, age-standardized incidence is approximately 0.5–0.8 per 100,000, though underdiagnosis and regional variability persist. Established risk factors include EBV seropositivity, HIV infection, autoimmune conditions (e.g., rheumatoid arthritis, celiac disease), family history (particularly monozygotic twins), and socioeconomic factors linked to delayed diagnosis. Quality of life (QoL) impact is substantial and multifaceted: early-stage patients often experience fatigue, night sweats, pruritus, and unexplained weight loss (‘B symptoms’), while treatment-related toxicities—including chemotherapy-induced neuropathy, infertility, secondary malignancies (e.g., AML, breast cancer), cardiovascular damage from mediastinal radiation, and persistent anxiety—significantly impair physical functioning, emotional well-being, and social engagement. Survivorship care increasingly emphasizes longitudinal monitoring, psychosocial support, fertility preservation, and lifestyle interventions to mitigate long-term morbidity. With modern risk-adapted therapy—including ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or AVD regimens, PET-guided response assessment, and emerging immunotherapies like brentuximab vedotin and checkpoint inhibitors—5-year overall survival exceeds 90% for early-stage and 75–85% for advanced-stage disease in high-resource settings. However, disparities in access to diagnostics, staging imaging (PET/CT), and specialized hematologic oncology care remain critical barriers to optimal outcomes in many regions of China.

Hodgkin lymphoma (HL) is a B-cell-derived hematologic malignancy characterized by the presence of clonal Reed-Sternberg cells within a reactive inflammatory microenvironment. As a highly curable neoplasm—especially in early-stage and favorable-risk disease—the standard of care relies on risk-adapted, multimodal therapy coordinated by hematologists-oncologists. Treatment strategies are stratified according to stage (Ann Arbor classification), bulk, symptom status (B-symptoms: fever >38°C, drenching night sweats, weight loss >10% in 6 months), age, comorbidities, and prognostic indices such as the International Prognostic Score (IPS). Conservative treatment is not applicable in the traditional sense—as HL is systemic and rarely indolent—but active surveillance is reserved exclusively for rare, incidentally discovered, asymptomatic Stage I nodular lymphocyte-predominant HL (NLPHL) with minimal disease burden; even then, close monitoring with PET-CT every 2–3 months is mandatory due to risk of progression. Most patients require definitive anti-neoplastic intervention.

First-line medication regimens are chemotherapy-based and tailored to risk. For early-stage favorable HL (Stage I–II, no adverse features), ABVD (doxorubicin 25 mg/m² IV day 1 & 15, bleomycin 10 U/m² IV day 1 & 15, vinblastine 6 mg/m² IV day 1 & 15, dacarbazine 375 mg/m² IV day 1 & 15) for two cycles followed by involved-site radiotherapy (ISRT) at 20–30 Gy is standard. In early-stage unfavorable or advanced-stage (III–IV) disease, six cycles of ABVD remain the global benchmark, with PET-CT after cycle 2 (interim PET) guiding response-adapted escalation or de-escalation. Patients with persistent FDG-avidity (Deauville score 4–5) may receive escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) or switch to brentuximab vedotin–AVD (A+AVD), which has demonstrated superior progression-free survival and reduced pulmonary toxicity versus ABVD in frontline advanced HL. Brentuximab vedotin—a CD30-directed antibody–drug conjugate—is now integrated into first-line therapy for high-risk patients and is standard in relapsed/refractory settings. Immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are FDA- and NMPA-approved for relapsed/refractory HL post-autologous stem cell transplantation (ASCT) or in transplant-ineligible patients, leveraging the characteristic PD-L1 amplification on Reed-Sternberg cells. Corticosteroids (e.g., prednisone) are adjunctive but not standalone agents; growth factors (e.g., pegfilgrastim) mitigate neutropenia. Supportive medications—including antiemetics (e.g., palonosetron + aprepitant), hydration protocols for tumor lysis prophylaxis, and pulmonary function monitoring during bleomycin administration—are integral to safe delivery.

Surgical treatment plays no primary therapeutic role in HL. Lymph node biopsy—typically excisional—is essential for diagnosis and histopathologic subtyping (e.g., nodular sclerosis vs. mixed cellularity), but resection is never curative. Surgery is limited to diagnostic purposes or palliation of complications (e.g., bowel obstruction from bulky abdominal disease, spinal cord decompression in vertebral involvement). Resection of residual masses post-chemotherapy is discouraged unless there is clinical or metabolic suspicion of transformation or residual viable tumor unconfirmed by PET-CT; in such cases, biopsy—not resection—is preferred. Minimally invasive techniques (e.g., video-assisted thoracoscopy) may be used for mediastinal biopsies but confer no survival advantage over core needle or surgical excision when adequate tissue is obtained.

China offers distinct advantages in HL management, anchored in centralized expertise, rapid diagnostic integration, and cost-effective innovation. Over 40 National Lymphoma Diagnosis and Treatment Centers—certified by the Chinese Society of Clinical Oncology (CSCO)—provide standardized, multidisciplinary care aligned with CSCO and NCCN guidelines. PET-CT access is widespread in tertiary hospitals, enabling precise staging and response assessment within 72 hours of referral. China’s robust generic drug ecosystem ensures affordability: biosimilar rituximab (for NLPHL variants) and domestically manufactured brentuximab vedotin (approved in 2022) reduce treatment costs by >40% versus imported counterparts. Clinical trial participation is high—over 120 active HL trials registered on ChiCTR include investigator-initiated studies evaluating novel combinations (e.g., PD-1 inhibitors plus lenalidomide) and optimized radiation dosing. Furthermore, China’s national health insurance covers first-line ABVD, A+AVD, and nivolumab for relapsed disease, significantly improving accessibility. Real-world data from the China Lymphoma Working Party demonstrate 5-year overall survival rates of 92% for early-stage and 83% for advanced-stage HL—comparable to Western cohorts—attributable to protocol adherence, timely ASCT (performed in >95% eligible patients within 6 months of relapse), and integrated Traditional Chinese Medicine (TCM) supportive care, including acupuncture for chemotherapy-induced neuropathy and herbal formulations (e.g., Huang Qin Tang) validated for gastrointestinal toxicity mitigation.

Recovery requires structured, longitudinal support. Patients should undergo surveillance with physical exam, CBC, LDH, and PET-CT every 3–6 months for 2 years, then annually up to year 5. Cardiac monitoring (echocardiogram or MUGA) is recommended at baseline and 5–10 years post-doxorubicin due to cumulative cardiotoxicity risk. Pulmonary function tests are advised before and after bleomycin. Fertility preservation counseling must occur pre-treatment: sperm/embryo cryopreservation for adolescents and young adults, as ABVD carries moderate gonadotoxicity. Vaccination status requires optimization—patients should receive inactivated influenza, pneumococcal (PCV20 or PPSV23), and SARS-CoV-2 vaccines ≥6 months post-chemotherapy; live vaccines are contraindicated for ≥24 months after immunosuppressive therapy. Lifestyle interventions include smoking cessation (critical given synergistic lung cancer risk with bleomycin/radiation), moderate aerobic exercise (150 min/week) to counter fatigue and sarcopenia, and Mediterranean-style nutrition to reduce inflammation. Psychosocial support is essential: >30% of survivors report anxiety or depression; referral to oncology social workers or cognitive behavioral therapy improves quality-of-life metrics. Long-term follow-up must screen for second malignancies (e.g., breast cancer in women irradiated <30 years, AML/MDS post-alkylators), thyroid dysfunction (post-neck radiation), and premature cardiovascular disease. Survivorship care plans—standardized in >85% of Grade III-A hospitals in China—include personalized risk stratification, genetic counseling for familial clustering, and seamless transition to primary care after year 5.